XERS
Xeris Pharmaceuticals Inc
10.10$
+0.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.6% | +4.3% | -1.5% | -3.2% | +0.6% | -2.4% | +6.1% | +10.6% | +3.6% | +2.2% | +5.1% | |
| – | -1.1% | +10.9% | -1.7% | -4.4% | +3.0% | -2.5% | +13.5% | +20.7% | +7.3% | +4.7% | +9.2% | |
| – | +46.2% | -7.1% | -8.1% | +2.8% | +20.9% | -18.4% | +1.4% | +54.5% | +21.2% | +0.6% | +8.9% | |
| – | +9.8% | +20.6% | -11.2% | -10.5% | +3.2% | -18.4% | +1.4% | +54.5% | +21.2% | +0.6% | +8.9% | |
| – | -14.7% | -4.5% | +13.4% | -3.1% | -1.8% | +14.6% | +14.5% | +1.3% | -5.0% | +10.3% | +3.2% | |
| – | +1.8% | +5.3% | +5.1% | +5.0% | +6.8% | +9.4% | +27.7% | +0.3% | +1.8% | +8.1% | +9.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.4% | -2.5% | -2.5% | -2.6% | -2.7% | -2.7% | -2.8% | -2.9% | -3.0% | -3.1% | -3.2% | |
| – | +1.7% | +5.0% | +1.5% | -0.5% | +0.9% | -0.6% | +1.0% | +4.8% | -0.3% | +2.5% | +11.2% | |
| – | +9.4% | -23.2% | +3.3% | +20.6% | +10.4% | -5.3% | +0.1% | +22.1% | -5.7% | +8.2% | +59.8% | |
| – | +47.7% | +32.3% | +14.8% | +297.6% | +0.4% | -14.7% | -65.9% | +0.6% | +0.6% | +0.6% | +1,017.7% | |
| – | -4.2% | -38.7% | -18.3% | +28.5% | -69.3% | +177.4% | +49.0% | -31.0% | -52.9% | +272.8% | -18.6% | |
| – | +0.3% | +20.3% | +0.4% | -6.2% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | -14.7% | |
| – | -275.5% | – | – | – | – | – | – | – | – | -5.0% | -174.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +1.7% | +5.6% | +0.4% | +0.1% | +2.2% | +2.3% | +13.9% | +1.4% | -1.4% | -2.7% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.